Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SOMAVERT 25 MG — DIN 02448831

PEGVISOMANT : 25 MG · PFIZER CANADA ULC · POWDER FOR SOLUTION ; KIT · wholesale supply in Canada

Health Canada status: MARKETED

What is SOMAVERT?

SOMAVERT 25 MG contains PEGVISOMANT : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02448831, held by PFIZER CANADA ULC, supplied as POWDER FOR SOLUTION ; KIT for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 10-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SOMAVERT used for?

SOMAVERT (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery, and/or radiation therapy or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels and to improve clinical signs and symptoms.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Pegvisomant cost around the world?

Pegvisomant is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
Australiaex-manufacturer18AUD███.██
Czechiamax producer price (ex-factory)15CZK███.██
SpainPVP con IVA (public price)55EUR███.██
Greeceproducer price (ex-factory)55EUR███.██
Italyprezzo al pubblico (classe A)55EUR███.██
Luxembourgreimbursement55EUR███.██
Norwaymax AUP (pharmacy retail)15NOK███.██
Saudi Arabiapublic13SAR███.██
Slovakiacategorised final price33EUR███.██
Romaniamax producer price22RON███.██

46 pack listings across 29 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Pegvisomant pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

Is there a generic Pegvisomant in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

Only one market authorization holder has a Canadian DIN containing Pegvisomant — 5 DINs, of which 5 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.

Market authorization holderDINsMarketedBrand namesPosition
PFIZER CANADA ULC55SOMAVERTSourceable in Canada

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label25 MG
Dosage formPOWDER FOR SOLUTION ; KIT
RouteSUBCUTANEOUS
Pack configuration (monograph)Packages of 1 vial or 30 vials with corresponding diluent pre-filled syringes.
Storagenull

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substancePegvisomant
ATC codeH01AX01
AHFS class68:30.08
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02448831
DIN (unpadded, as printed on some documents)2448831
Brand nameSOMAVERT
Generic / active ingredientPEGVISOMANT : 25 MG
Market authorization holderPFIZER CANADA ULC
Health Canada schedulePrescription
ATC codeH01AX01
ATC anatomical main groupH — Systemic hormonal preparations
ATC therapeutic subgroupH01AX
Current statusMARKETED
Status date10-Mar-2016
Original market date2016-03-10 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

5 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
SOMAVERT10 MGPOWDER FOR SOLUTION ; KITPFIZER CANADA ULCMARKETED02272199
SOMAVERT15 MGPOWDER FOR SOLUTION ; KITPFIZER CANADA ULCMARKETED02272202
SOMAVERT20 MGPOWDER FOR SOLUTION ; KITPFIZER CANADA ULCMARKETED02272210
SOMAVERT30 MGPOWDER FOR SOLUTION ; KITPFIZER CANADA ULCMARKETED02448858

2 · Same class — other molecules in ATC H01AX

MoleculeCanadian brandsDINsMarketedSourceable
PegvisomantSOMAVERT55Yes

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC H01A

ATC subgroupMoleculesDINsMarketed
H01ACMecasermin · Somapacitan · Somatrem · Somatrogon · Somatropin · +1 more6127
H01AACorticotrophin · Tetracosactide41
H01ABThyrotrophin Alfa11

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SOMAVERT

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02448831. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.